<DOC>
	<DOCNO>NCT02321579</DOCNO>
	<brief_summary>This study design hospital-based cross-sectional randomize placebo-controlled intervention trial . One hundred fifty patient either cirrhosis cirrhosis combine hepatocellular carcinoma ( HCC ) meet inclusion criterion recruit Taichung General Veterans Hospital . One hundred patient randomly assign either 1 ) placebo group ( n = 25 ) ; 2 ) vitamin B-6 group ; ( 50 mg/d , n = 25 ) ; 3 ) glutathione ( GSH ) group ( 500 mg/d , n = 25 ) ; 4 ) vitamin B-6 ( 50 mg/d ) plus GSH ( 500 mg/d ) group ( n = 25 ) 3 mo . Data demography , anthropometry medical history collect . Patients cirrhosis cirrhosis combine HCC fast blood drawn clinic . Additionally , patient participate intervention study blood draw month 0 , 1 , 2 3 intervention period . Hematological measurement , plasma vitamin B-6 status , GSH , inflammatory marker , homocysteine , cysteine , SAM , SAH , oxidative stress indicator , oxidize GSH GSH relate antioxidant enzyme activity analyze .</brief_summary>
	<brief_title>Vitamin B-6 Glutathione Inflammation , Homocysteine , Oxidative Stress Antioxidant Capacities</brief_title>
	<detailed_description>Liver cirrhosis ninth lead cause death hepatocellular carcinoma ( HCC ) second leading cause cancer mortality among men woman Taiwan . Vitamin B-6 glutathione ( GSH ) metabolize liver , role vitamin B-6 GSH play inflammatory response antioxidant function would impair hepatic injury . The purpose study go assess effect individual combined supplementation vitamin B-6 GSH homocysteine , cysteine , ratio S-adenosylmethionine ( SAM ) /S-adenosylhomocysteine ( SAH ) , oxidative stress , oxidize glutathione ( GSSG ) GSH relate antioxidant enzyme activity patient cirrhosis cirrhosis combine HCC . This study design hospital-based cross-sectional randomize placebo-controlled intervention trial . One hundred fifty patient either cirrhosis cirrhosis combine HCC meet inclusion criterion recruit Taichung General Veterans Hospital . One hundred patient randomly assign either 1 ) placebo group ( n = 25 ) ; 2 ) vitamin B-6 group ; ( 50 mg/d , n = 25 ) ; 3 ) GSH group ( 500 mg/d , n = 25 ) ; 4 ) vitamin B-6 ( 50 mg/d ) plus GSH ( 500 mg/d ) group ( n = 25 ) 3 mo . Data demography , anthropometry medical history collect . Patients cirrhosis cirrhosis combine HCC fast blood drawn clinic . Additionally , patient participate intervention study blood draw month 0 , 1 , 2 3 intervention period . Hematological , plasma vitamin B-6 status , GSH , inflammatory marker , homocysteine , cysteine , SAM , SAH , oxidative stress indicator , GSSG GSH relate antioxidant enzyme activity measure . Hopefully , result study could provide picture beneficial effect vitamin B-6 GSH supplementation inflammatory response , homocysteine , cysteine , ratio SAM/SAH , oxidative stress , GSSG GSH relate antioxidant enzyme activity patient cirrhosis HCC .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1. age 20 80 year old 2. patient diagnosed cirrhosis cirrhosis combine hepatocellular carcimoma 1. patient currently take nutrient supplement 2. patient cardiac , renal , gastrointestinal diabetic disease 3. patient currently take medication interfere vitamin B6 glutathione metabolismã€”i.e. , phenobarbital , phenytoin , cycloserine , pyrazinamide , isoniazid , ( thio ) semicarbazide , hydramitrazine , phenelzine , carbidopa , levodopa , hydralazine , steroid penicillamine ) 4. patient pregnant lactation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>